Sanara MedTech Inc. (SMTI): Results of Operations and Financial Condition
Sanara MedTech Inc. (SMTI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited) FORT WORTH, TX, August 11, 2026 (GLOBE NEWSWIRE) — Sanara MedTech Inc. (“Sanara,” “Sanara MedTech,” the “Company,” “we,” “our” or “us”) (Nasdaq: SMTI), a medical technology company focused
How this was made
The 30-second read
Why it matters
SMTI’s disclosure includes both operating performance metrics for Q2 2026 and a newly announced acquisition agreement expected to be acquired by MIMEDX, which can dominate near-term trading due to deal probability and terms uncertainty.
Market read
Traders get a fresh earnings snapshot plus a newly disclosed acquisition catalyst, supporting both fundamental and event-driven positioning.
What to watch
Closing conditions and timing are not provided in the excerpt; traders may need to monitor definitive agreement terms, regulatory/contractual hurdles, and any impact on the planned 1Q 2027 product introduction.
Sanara MedTech Inc. Reports Second Quarter 2026 Financial Results (Unaudited)
Net revenue increased 9% and gross margin improved to 93%, while operating income declined to $1.8 million and the company reported a net loss from continuing operations of $0.4 million, driven by higher SG&A, interest expense and equity-method investment losses.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Net revenueGAAP | $28.1 million | – | 9% |
| Gross profitGAAP | $26.2 million | – | 10% |
| Gross marginGAAP | 93% of net revenue | – | – |
| Operating expensesGAAP | $24.4 million, or 86.8% of net revenue | – | 14% |
| Research and development expenseGAAP | $1.2 million, or 4% of net revenue | – | – |
| Operating incomeGAAP | $1.8 million | – | – |
| Other expenseGAAP | $2.2 million | – | – |
| Net loss from continuing operationsGAAP | $0.4 million | – | – |
| Loss per diluted share from continuing operationsGAAP | a loss of $0.05 per diluted share | – | – |
| Net loss from discontinued operationsGAAP | $41,720 | – | – |
| Adjusted EBITDAnon-GAAP | $5.0 million | – | $0.3 million |
| First six months net revenueGAAP | $55.9 million | – | 14% |
| First six months gross profitGAAP | $52.0 million | – | 14% |
| First six months gross marginGAAP | 93% of net revenue | – | – |
| First six months operating expensesGAAP | $47.6 million, or 85.2% of net revenue | – | 13% |
| First six months research and development expenseGAAP | $1.9 million, or 3% of net revenue | – | – |
| First six months operating incomeGAAP | $4.4 million | – | – |
| First six months other expenseGAAP | $4.4 million | – | – |
| First six months net loss from continuing operationsGAAP | $13,457 | – | – |
| First six months diluted earnings per share from continuing operationsGAAP | zero per diluted share | – | – |
| First six months net income from discontinued operationsGAAP | $19,196 | – | – |
| First six months Adjusted EBITDAnon-GAAP | $9.3 million | – | $1.9 million |
Segments
| Segment | Revenue | q/q | y/y |
|---|---|---|---|
| Soft tissue repair productsSales of CellerateRX Surgical, BIASURGE and FORTIFY TRG increased. | $25,242,592 | – | an increase of $2.5 million, or 11% |
| Bone fusion productsSales declined in the second quarter of 2026. | $2,894,165 | – | a slight decrease of $0.2 million, or 8% |
What drove it
- Higher net revenue was driven by increased sales of soft tissue repair products, including CellerateRX Surgical, BIASURGE and FORTIFY TRG.
- Higher gross profit and margin were primarily due to revenue growth factors and product mix.
- Higher SG&A reflected increased direct sales and marketing expenses, compensation expense, and legal and advisory services associated with corporate strategic initiatives.
- Other expense increased primarily because of higher interest expense on the CRG Term Loan and the share of losses from equity method investments.
- Interest on the CRG Term Loan was paid-in-kind and capitalized to the loan balance in the second quarter of 2025, whereas all interest was paid in cash in the second quarter of 2026.
Concerns
- Operating expenses increased 14% year-over-year to $24.4 million, or 86.8% of net revenue.
- Operating income declined to $1.8 million from $2.5 million.
- The company reported a net loss from continuing operations of $0.4 million, compared with net income from continuing operations of $0.5 million.
- Bone fusion product sales decreased $0.2 million, or 8%, year-over-year.
- The proposed acquisition by MIMEDX remains subject to customary closing conditions.
What to watch
- Completion of the proposed acquisition by MIMEDX, which remains subject to customary closing conditions.
- Continued penetration of CellerateRX Surgical, BIASURGE and FORTIFY TRG.
- Bone fusion product sales trends.
- Direct sales and marketing expenses, compensation expense, and legal and advisory services associated with corporate strategic initiatives.
- Introduction of OsStic, which management stated remains on track for the first quarter of 2027.
Balance sheet and cash flow
- Cash and cash equivalents of $15.4 million at June 30, 2026, compared to $16.6 million of cash and cash equivalents at December 31, 2025.
- $46.5 million of long-term debt at June 30, 2026, compared to $46.0 million of long-term debt at December 31, 2025.
Analysis
Second-quarter demand was led by soft tissue repair products. Net revenue increased 9% to $28.1 million, as soft tissue repair product sales increased $2.5 million, or 11%, supported by CellerateRX Surgical, BIASURGE and FORTIFY TRG. This was partly offset by a $0.2 million, or 8%, decrease in bone fusion product sales. First-six-month net revenue increased 14% to $55.9 million, also led by soft tissue repair products.
Gross profit increased 10% to $26.2 million and gross margin improved to 93% of net revenue from 92% of net revenue. Management attributed the improvement to revenue growth factors and product mix. Adjusted EBITDA increased to $5.0 million from $4.7 million, indicating that higher gross profit supported non-GAAP earnings despite cost growth.
The GAAP earnings profile weakened in the quarter. Operating expenses increased 14% to $24.4 million, or 86.8% of net revenue, with higher direct sales and marketing, compensation, and legal and advisory costs associated with corporate strategic initiatives. Operating income declined to $1.8 million from $2.5 million. Higher CRG Term Loan interest expense and equity-method investment losses increased other expense to $2.2 million, contributing to a $0.4 million net loss from continuing operations compared with $0.5 million of income in the prior-year period.
Cash and cash equivalents were $15.4 million at June 30, 2026, compared with $16.6 million at December 31, 2025, while long-term debt was $46.5 million compared with $46.0 million. The filing states that CRG Term Loan interest was paid in cash in 2026, versus paid-in-kind and capitalized in the comparable 2025 period. No financial outlook was provided. The principal operating milestones are continued surgical-portfolio penetration, bone fusion sales performance, the proposed MIMEDX acquisition subject to customary closing conditions, and the planned first-quarter 2027 OsStic launch.
Management, verbatim
We continued to drive solid revenue growth in the second quarter of 2026 with net revenue of $28.1 million, representing a 9% increase over the second quarter of 2025, as well as gross margin of 93% supporting Adjusted EBITDA of $5.0 million.
Seth Yon, President and Chief Executive Officer
The completion of this combination, which remains subject to customary closing conditions, would allow us to deepen our existing distributor relationships and expand our operating presence by bringing together two highly focused organizations with deep benches of talent and strong momentum in the surgical space.
Seth Yon, President and Chief Executive Officer
We remain focused on continuing to meet the needs of our customers and expanding penetration of our portfolio of surgical products, which include our leading product CellerateRX Surgical, BIASURGE and OsStic, a licensed synthetic injectable structural bio-adhesive bone void filler which remains on track to be introduced to the market in the first quarter of 2027.
Seth Yon, President and Chief Executive Officer
Not in the filing
stated, not guessed- Financial guidance for future periods.
- Prior-quarter comparisons for reported operating metrics.
- Operating cash flow.
- Free cash flow.
- Capital returns, including share repurchases and dividends.
- Quarterly non-GAAP earnings per share.
- Tax rate.
- Adjusted EBITDA reconciliation, which was referenced but not included in the provided filing text.
AlphAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Q2 2026 financial results and an attached exhibit containing management commentary.
Ticker impact
Sanara (SMTI) reported Q2 2026 results and disclosed a transformational agreement expected to be acquired by MIMEDX.
Likely positive bias on deal expectations, with volatility driven by closing-condition uncertainty and integration assumptions.
The filing includes specific Q2 financial metrics plus a newly announced acquisition agreement expected to close subject to customary conditions.
Market effects
Could shift sentiment in surgical regenerative medicine and wound-care adjacent medtech peers via read-through on consolidation appetite.
Limited direct regional impact; primarily US-listed medtech sentiment.
Moderate, as the deal is US-focused but may affect global regenerative medicine competitive positioning.
Counterpoint
Revenue and gross margin strength may be offset by rising operating expenses and net loss from continuing operations, so the deal may be the main driver rather than improving standalone profitability.
Key entities
- companySanara MedTech Inc.
Nasdaq-listed medical technology company reporting Q2 2026 results and announcing an acquisition agreement expected with MIMEDX.
- companyMIMEDX
Wound-care and surgical products provider named as the expected acquirer of Sanara under a transformational agreement.
- counterpartyCRG Servicing LLC
Referenced as the term-loan servicer; interest expense increased due to cash interest in Q2 2026.
